Dataset Information


Decursin Alleviates Mechanical Allodynia in a Paclitaxel-Induced Neuropathic Pain Mouse Model.

ABSTRACT: Chemotherapy-induced neuropathic pain (CINP) is a severe adverse effect of platinum- and taxane-derived anticancer drugs. The pathophysiology of CINP includes damage to neuronal networks and dysregulation of signal transduction due to abnormal Ca2+ levels. Therefore, methods that aid the recovery of neuronal networks could represent a potential treatment for CINP. We developed a mouse model of paclitaxel-induced peripheral neuropathy, representing CINP, to examine whether intrathecal injection of decursin could be effective in treating CINP. We found that decursin reduced capsaicin-induced intracellular Ca2+ levels in F11 cells and stimulated neurite outgrowth in a concentration-dependent manner. Decursin directly reduced mechanical allodynia, and this improvement was even greater with a higher frequency of injections. Subsequently, we investigated whether decursin interacts with the transient receptor potential vanilloid 1 (TRPV1). The web server SwissTargetPrediction predicted that TRPV1 is one of the target proteins that may enable the effective treatment of CINP. Furthermore, we discovered that decursin acts as a TRPV1 antagonist. Therefore, we demonstrated that decursin may be an important compound for the treatment of paclitaxel-induced neuropathic pain that functions via TRPV1 inhibition and recovery of damaged neuronal networks.

PROVIDER: S-EPMC8001788 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8618121 | BioStudies
| S-EPMC8116404 | BioStudies
| S-EPMC6722212 | BioStudies
| S-EPMC7249139 | BioStudies
| S-EPMC8085838 | BioStudies
| S-EPMC7585293 | BioStudies
| S-EPMC5341238 | BioStudies
| S-EPMC6043616 | BioStudies
| S-EPMC6816046 | BioStudies
| S-EPMC8759107 | BioStudies